THE USE OF SEMAGLUTIDE MEDICINE AS AN ALLY THE TREATMENT OF OBESITY
DOI:
https://doi.org/10.47820/recima21.v4i2.2731Keywords:
Semaglutide, obesity, diabetes, nutritionAbstract
Objective - The goal of this study is to evaluate the side effects of the indiscriminate use of the drug semaglutide, as well as its impacts on health and consequences arising. Methods - This is a descriptive bibliographic review, made through a bibliographic survey in the databases of Pubmed, Medline, Lilacs, Scielo, Google Scholar. Literature Review - According to the World Health Organization (WHO), obesity is considered a global, multifactorial disease characterized by excessive accumulation of adipose tissue. Among its forms of treatment, pharmacotherapy gained prominence, mainly to facilitate weight loss. Semaglutide is a recent drug, used in the treatment of type 2 diabetes mellitus (DM2), a GLP-1 analogue, that has an appetite suppressant effect, reducing serum glucose levels, causing the loss of weight. Nonetheless, obesity can’t be treated in a safe and sustainable way without proper diet therapy, nutritional education, physical activities and other actions that involve the need for a multidisciplinary team to treat a disease that is multifactorial. Conclusion - The use of semaglutide as an anorectic is a drug with potential in reducing body weight, there are side effects, drug interactions and contraindications. It was noted that the effectiveness of the treatment is positive and lasting when combined with individualized dietary protocol and guided physical activity practices.
Downloads
References
ABESO - Associação Brasileira para Estudo da Obesidade e Síndrome Metabólica. Diretrizes Brasileiras de Obesidade 2016. VI Diretrizes Bras. Obesidade. 2016; 4o edição:7–186.
Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obes. Metab. 2018;20(9):2210–19.
Aroda VR, Bauer R, Christiansen E, Haluzík M, Kallenbach K, Montanya E, et al. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes, Obes. Metab. 2022;24(December 2021):1338–50.
Niman S, Hardy J, Goldfaden RF, Reid J, Sheikh-Ali M, Sutton D, et al. A Review on the Efficacy and Safety of Oral Semaglutide. Drugs R D. 2021;21(2):133–48.
Zhang D, Lv G. Therapeutic potential of spinal GLP-1 receptor signaling. Peptides. 2018;101(September 2017):89–94.
Rizvi AA, Rizzo M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes, Metab. Syndr. Obes. Targets Ther. 2022;15(April):1023–30.
Yaribeygi H, Rashidy-Pour A, Atkin SL, Jamialahmadi T, Sahebkar A. GLP-1 mimetics and cognition. Life Sci. 2021;264(July):1–7.
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obes. Metab. 2021;23(3):754–62.
Snitker S, Egebjerg C, Frederiksen M, Sparre T. Ease-of-use and acceptability of the novel semaglutide 2 . 4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial. Diabetes, Metab. Syndr. Obes. 2022;2:1–14.
Tezoto MF, Muniz BV. Atenção Farmaceutica em Pacientes Obesos, com Foco na Orientação Correta ao Uso dos Anorexígenos. Rev. científica eletrónica Ciências Apl. da FAIT. 2020;2:1–15.
Iłowiecka K, Glibowski P, Skrzypek M, Styk W. The Long‐Term Dietitian and Psychological Support of Obese Patients Who Have Reduced Their Weight Allows Them to Maintain the Effects. Nutrients. 2021;13(6):1–22.
Lau DCW, Batterham RL, Roux CW le. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev. Clin. Pharmacol. 2022;15(3):251–68.
Martínez R, López-Trinidad LM, Kapravelou G, Arrebola F, Galisteo M, Aranda P, et al. A combined healthy strategy for successful weight loss, weight maintenance and improvement of hepatic lipid metabolism. J. Nutr. Biochem. 2020;85:1–13.
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: A clinical practice guideline. Cmaj. 2020;192(31):875–91.
Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LF Van, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021;384(11):989–1002.
Costa R, Carvalho LRA de, Lima ND de, Costa TP de C, Onyeisi JOS. Avaliação do Consumo de Medicamentos para o Tratamento da Obesidade: Um Estudo realizado em Farmácias do Município de Teresina-Piauí. Res. Soc. Dev. 2020;9(3):1–17.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
